ENVERIC BIOSCIENCES, INC. Capital Expenditures
ENVERIC BIOSCIENCES, INC. (ENVB) reported Capital Expenditures of $5.18 thousand for the 12-month period ending 2023-12-31, per its 10-K filed 2025-03-28.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquirePropertyPlantAndEquipment · last filed 2025-03-28
- ENVERIC BIOSCIENCES, INC. payments to acquire property, plant, and equipment for the quarter ending 2023-12-31 was -$15.00, a 100.24% decline year-over-year.
- ENVERIC BIOSCIENCES, INC. payments to acquire property, plant, and equipment for the quarter ending 2023-09-30 was $8.00, a 99.96% decline year-over-year.
- ENVERIC BIOSCIENCES, INC. payments to acquire property, plant, and equipment for the quarter ending 2023-06-30 was $18.00, a 99.97% decline year-over-year.
- ENVERIC BIOSCIENCES, INC. payments to acquire property, plant, and equipment for the quarter ending 2023-03-31 was $5.17K, a 98.98% decline year-over-year.
- ENVERIC BIOSCIENCES, INC. payments to acquire property, plant, and equipment for fiscal 2023 was $5.18K, a 99.11% decline from fiscal 2022.
- ENVERIC BIOSCIENCES, INC. payments to acquire property, plant, and equipment for fiscal 2022 was $584.16K, a 207.91% increase from fiscal 2021.
- ENVERIC BIOSCIENCES, INC. payments to acquire property, plant, and equipment for fiscal 2021 was $189.72K.
| Period end | Payments to Acquire Property, Plant, and Equipment 3 month | Payments to Acquire Property, Plant, and Equipment 6 month | Payments to Acquire Property, Plant, and Equipment 9 month | Payments to Acquire Property, Plant, and Equipment 12 month |
|---|---|---|---|---|
| 2023-12-31 | -$15.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28 | -$7.00 derived: sum of 2 quarters · filed 2025-03-28 | $11.00 derived: sum of 3 quarters · filed 2025-03-28 | $5.18K 10-K · filed 2025-03-28 |
| 2023-09-30 | $8.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $26.00 derived: sum of 2 quarters · filed 2024-11-14 | $5.20K 10-Q · filed 2024-11-14 | $11.39K derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | $18.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | $5.19K 10-Q · filed 2024-08-12 | $11.38K derived: sum of 3 quarters · filed 2024-08-12 | $29.95K derived: sum of 4 quarters · filed 2024-08-12 |
| 2023-03-31 | $5.17K 10-Q · filed 2024-05-15 | $11.36K derived: sum of 2 quarters · filed 2024-05-15 | $29.94K derived: sum of 3 quarters · filed 2024-05-15 | $83.83K derived: sum of 4 quarters · filed 2024-05-15 |
| 2022-12-31 | $6.19K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-26 | $24.77K derived: sum of 2 quarters · filed 2024-03-26 | $78.66K derived: sum of 3 quarters · filed 2024-03-26 | $584.16K 10-K · filed 2024-03-26 |
| 2022-09-30 | $18.57K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $72.47K derived: sum of 2 quarters · filed 2023-11-13 | $577.97K 10-Q · filed 2023-11-13 | |
| 2022-06-30 | $53.89K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-11 | $559.40K 10-Q · filed 2023-08-11 | ||
| 2022-03-31 | $505.51K 10-Q · filed 2023-05-15 | |||
| 2021-12-31 | $189.72K 10-K/A · filed 2023-06-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |